BioLineRx Announces Collaboration with MSD
News Jan 13, 2016
BioLineRx Ltd. has announced a collaboration with MSD, known as Merck in the US and Canada, to support a Phase 2 study investigating BioLineRx's BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with metastatic pancreatic cancer.
The study is an open-label, multicenter, single-arm trial designed to evaluate the safety and efficacy of this combination in patients with metastatic pancreatic adenocarcinoma.
BL-8040, BioLineRx's lead oncology platform, is a CXCR4 antagonist that has been shown in several clinical trials to be a robust mobilizer of immune cells and to be effective at inducing direct tumor cell death. Additional findings in the field of immuno-oncology suggest that CXCR4 antagonists may be effective in inducing the migration of anti-tumor T cells into the tumor micro-environment. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to help detect and fight tumor cells.
KEYTRUDA blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T- lymphocytes, which may affect both tumor cells and healthy cells. The Phase 2 study will evaluate the clinical response, safety and tolerability of the combination of these therapies as well as multiple pharmacodynamic parameters, including the ability to improve infiltration of T cells into the tumor and their reactivity.
"We are extremely happy to collaborate with MSD, a pioneer and world leader in cancer immunotherapy. This marks the entrance of BL-8040 into this exciting field, which is already transforming the lives of many cancer patients," stated Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx. "Because certain tumors exhibit only a modest response to existing immunotherapies, we are increasingly seeing clinical studies involving combinations of immuno-oncology agents with other classes of drugs. We are initiating this study with the hope that it will show that the combination of BL-8040 with KEYTRUDA has the potential to expand the benefit of immunotherapy to cancer types currently resistant to immuno-oncology treatments, such as pancreatic cancer, which represents a significant unmet medical need. If this potential can be realized, it will be an extremely important advance in the fight against cancer, as well as a seminal milestone for BioLineRx."
"Today, there is a great opportunity and need to bring forward new scientific breakthroughs for the treatment of pancreatic cancer," said Dr. Eric Rubin, vice president and therapeutic area head, oncology early-stage development, MSD Research Laboratories. "Evaluating the potential of combination therapies through strategic collaborations in difficult-to-treat tumor types continues to be an important part of our immuno-oncology clinical development program for KEYTRUDA."
The agreement is between BioLineRx and MSD, through a subsidiary. Per the terms of the agreement, the trial will be sponsored and performed by BioLineRx. The study is planned to commence by mid-2016. Upon completion of the study, or at any earlier point, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
Macrophage's Role in Maintaining Tattoos Could Hold Key to RemovalNews
Researchers have discovered that, though a tattoo may be forever, the skin cells that carry the tattoo pigment are not. Instead, the cells can pass on the pigment to new cells when they die. The study suggests ways to improve the ability of laser surgery to remove unwanted tattoos.READ MORE
Neuroblastoma Biomarker Research Advances TreatmentNews
Neuroblastoma, a childhood cancer, is treatable in less than half of aggressive cases, but new RNA biomarkers may help identify high-risk patients faster and lead to better prognosis.READ MORE
New Causes of Cellular Decline in Prematurely Aging Kids DiscoveredNews
In a recent paper published in Cell Reports, Saint Louis University researchers have uncovered new answers about why cells rapidly age in children with a rare and fatal disease. The data points to cellular replication stress and a mistaken innate immune response as culprits, and the team found success in the laboratory in blocking these processes with vitamin D.READ MORE